Asset Details
Do you wish to reserve the book?
The use of ketamine as a neuroprotective agent following cardiac arrest: A scoping review of current literature
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The use of ketamine as a neuroprotective agent following cardiac arrest: A scoping review of current literature
Do you wish to request the book?
The use of ketamine as a neuroprotective agent following cardiac arrest: A scoping review of current literature
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The use of ketamine as a neuroprotective agent following cardiac arrest: A scoping review of current literature
2023
Overview
Aims The objective of this article is to summarize the state of the literature surrounding the use of ketamine as a neuroprotective agent following cardiac arrest. Methods Five electronic databases were used to search for studies related to the use of ketamine for neuroprotection following cardiac arrest. This search was performed once in May 2020, and an updated search was conducted in May 2021 and March 2022. Results All searches combined retrieved 181 results; no clinical trials were identified. As such, the authors were limited to writing a scoping review of the literature rather than a systematic review. Conclusions The current state of the literature describes the mechanism of action of ketamine as a neuroprotective agent through its action as an NMDA antagonist. There is evidence of its efficacy as a neuroprotective agent in preclinical models of cardiac arrest. Current published clinical work supports the use of ketamine ameliorating neurologic outcomes in other conditions such as epilepsy, traumatic brain injury, and depression. The current state of the literature is reflective of the notion that the use of ketamine following cardiac arrest may result in improved neurologic outcomes. Future research directions should focus on the use of ketamine as a possible clinical intervention following cardiac arrest. Ketamine holds promise as a neuroprotective agent through attenuating damage caused by the excitotoxic cascade. Though extensively studied in a stroke model, application to post‐cardiac arrest brain injury has been overlooked. This scoping review summarizes the mechanism of ketamine neuroprotection as applicable to post‐cardiac arrest brain injury, and existing evidence for the benefits of its use.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
/ Brain Injuries, Traumatic - drug therapy
/ cardiopulmonary resuscitation
/ Epilepsy
/ Glutamic acid receptors (ionotropic)
/ Heart
/ Heart Arrest - complications
/ Humans
/ Ischemia
/ Ketamine
/ N-Methyl-D-aspartic acid receptors
/ Neuroprotective Agents - pharmacology
/ Neuroprotective Agents - therapeutic use
/ Original
/ Patients
